MRI contrast developer Epix Pharmaceuticals of Lexington, MA, has announced that holders of its $3.2 million outstanding balance of stock due 2024 can require Epix to repurchase the notes on August 5 of this year.
The Nasdaq stock exchange delisted Epix in May, giving shareholders the right to sell their shares back to the company, according to Epix.
Related Reading
Nasdaq delists Epix stock, May 14, 2009
Epix to pursue strategic alternatives, May 12, 2009
Epix to complete tender offer, May 5, 2009
Epix works to avoid bankruptcy, April 9, 2009
Lantheus buys Epix's MS-325 rights, April 7, 2009
Copyright © 2009 AuntMinnie.com
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
